{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T22:15:49Z","timestamp":1726179349920},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CPD"],"published-print":{"date-parts":[[2004,5,1]]},"DOI":"10.2174\/1381612043384646","type":"journal-article","created":{"date-parts":[[2005,3,17]],"date-time":"2005-03-17T23:27:07Z","timestamp":1111102027000},"page":"1577-1585","source":"Crossref","is-referenced-by-count":2,"title":["Intravenous Glycoprotein IIb \/ IIIa Antagonists: Their Benefits, Problems and Future Developments"],"prefix":"10.2174","volume":"10","author":[{"given":"Ronan","family":"Curtin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/62677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T09:29:28Z","timestamp":1448011768000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1381-6128&volume=10&issue=14&spage=1577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":0,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2004,5,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612043384646","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5,1]]}}}